Cancer Gene Therapy

Retinoblastoma Gene Therapy Inhibits Tumor Growth In Vivo

Published in Cancer Weekly, September 28th, 1998

Tumor growth was inhibited both in vitro and in vivo by a recombinant adenoviral vector expressing full-length human retinoblastoma susceptibility gene.

The human retinoblastoma gene, RB1, is one of the most well-characterized tumor-suppressor genes. The RB1 gene product, RB protein, causes cell cycle arrest in the G₀ /G₁ phase by inhibiting transcription factors.

As a prelude to considering RB gene therapy for cancer, G. William Demers and colleagues from Canji, Inc., California, and the Schering-Plough Research Institute, New Jersey, conducted a series of in vitro and in vivo experiments using a recombinant...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1998-09-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry